Genentech struck a strategic deal with DualityBio to pursue antibody-drug conjugates aimed at ADC-resistant cancers. Roche’s unit will pay $45 million upfront, with the overall transaction valued at more than $1 billion in potential milestones. The pact targets a growing subgroup of patients who have progressed after prior ADC treatment, an area where response durability remains a central unmet need. By buying early rights tied to DualityBio’s ADC-resistance approach, Genentech is signaling a push toward next-generation ADC mechanisms designed to circumvent post-treatment escape pathways.